Compare STEM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | RNAZ |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 27.9M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | RNAZ |
|---|---|---|
| Price | $2.38 | $1.66 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 165.5K | 30.2K |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.15 | $1.52 |
| 52 Week High | $22.12 | $12.60 |
| Indicator | STEM | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 25.49 | 41.36 |
| Support Level | N/A | $1.57 |
| Resistance Level | $6.02 | $1.95 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 13.14 | 12.20 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.